Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

ARK Invest CEO Cathie Wood reaffirmed her firm’s long-term bullish outlook for Bitcoin, projecting a base case of approximately $750,000 and a bull case of $1,250,000 within the next five years, even ...

The singer died on Friday after a “private battle with cancer,” according to his official Instagram account. By Rylee Kirk See more of our coverage in your search results.Encuentra más de nuestra ...

Evercore ISI sets a base case S&P 500 target of 7,750 for year-end 2026, with a 30% chance of a bull case reaching 9,000. AI-driven gains in tech, communication services, and consumer discretionary ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Max Layton, Citi global head of commodities research, joins 'Squawk Box' to discuss the impact of the Iran war on the energy market, what the best/worst case scenarios for the oil market are, and more ...

LONDON, March 6 (Reuters Breakingviews) - What endgame for Iran are investors pricing in? Judging by moves in financial markets since U.S. President Donald Trump and Israeli Prime Minister Benjamin ...

Recursive Language Models aim to break the usual trade off between context length, accuracy and cost in large language models. Instead of forcing a model to read a giant prompt in one pass, RLMs treat ...

Citigroup's base case for bitcoin (BTC) is a rise to $143,000 in 12 months. Analysts highlight $70,000 as key support, with the potential for a sharp rise due to revived ETF demand and positive market ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...